Prelude Therapeutics Incorporated (PRLD) - חוב לטווח ארוך להון

Prelude Therapeutics (PRLD) is implementing robotic bioscreening to accelerate the development of oncology drugs. The ratio of long-term loans to equity illustrates financial stability, where 0.12 serves as the current metric level. Future profit is based on the commercialization of targeted inhibitors for the treatment of lymphomas. Profit potential relies on the development of small-molecule agents that correct genetic malfunctions in tumor cells.

Investors use this ratio to assess financial stability and the extent of the company's reliance on external borrowings. The metric is calculated as the ratio of liabilities with a maturity of more than one year to equity. By analyzing the trend of the long-term debt-to-equity ratio, one can track changes in the credit load. For Prelude Therapeutics (PRLD), this is critical during the development of selective PRMT5 inhibitors. A low level of borrowing confirms the company's ability to fund oncology innovations using its own resources.